| Literature DB >> 32617649 |
Bertrand Cariou1, Samy Hadjadj2, Matthieu Wargny3,4, Matthieu Pichelin3, Abdallah Al-Salameh5, Ingrid Allix6, Coralie Amadou7, Gwénaëlle Arnault8, Florence Baudoux9, Bernard Bauduceau10,11, Sophie Borot12, Muriel Bourgeon-Ghittori13, Olivier Bourron14, David Boutoille15, France Cazenave-Roblot16,17, Claude Chaumeil18, Emmanuel Cosson19,20, Sandrine Coudol4, Patrice Darmon21, Emmanuel Disse22, Amélie Ducet-Boiffard23, Bénédicte Gaborit24, Michael Joubert25, Véronique Kerlan26, Bruno Laviolle27, Lucien Marchand28, Laurent Meyer29, Louis Potier30, Gaëtan Prevost31, Jean-Pierre Riveline32,33,34, René Robert35, Pierre-Jean Saulnier36, Ariane Sultan37, Jean-François Thébaut18, Charles Thivolet38,39, Blandine Tramunt40, Camille Vatier41,42, Ronan Roussel30, Jean-François Gautier32,34, Pierre Gourdy40.
Abstract
The authors regret a mistake in Table 1.Entities:
Year: 2020 PMID： 32617649 PMCID： PMC7330254 DOI： 10.1007/s00125-020-05207-3
Source DB: PubMed Journal: Diabetologia ISSN： 0012-186X Impact factor: 10.122
Clinical characteristics prior to admission of CORONADO participants, according to primary outcome (tracheal intubation and/or death within 7 days of admission), and death on day 7
| Clinical features | Number of people with available data | All | Primary outcome ( | Death ( |
|---|---|---|---|---|
| Sex (female/male) | 1317 | 462/1317 (35.1) | 0.77 (0.60, 0.99) | 0.80 (0.55, 1.17) |
| Age (years) | 1317 | 69.8 ± 13.0 | 1.00 (0.99, 1.01) | 1.09 (1.07, 1.11) |
| Age class (years) | 1317 | |||
| < 55 | 159/1317 (12.1) | 1 | 1 | |
| 55–64 | 266/1317 (20.2) | 0.58 (0.38, 0.90) | 1.00 (0.23, 4.23) | |
| 65–74 | 394/1317 (29.9) | 0.89 (0.60, 1.31) | 3.22 (0.95, 10.1) | |
| ≥ 75 | 498/1317 (37.8) | 0.85 (0.58, 1.24) | 14.6 (4.56, 46.6) | |
| Type of diabetes | 1317 | |||
| Type 2 | 1166/1317 (88.5) | 1 | 1 | |
| Type 1 | 39/1317 (3.0) | 0.73 (0.35, 1.56) | 0.44 (0.11, 1.86) | |
| Other | 71/1317 (5.4) | 1.33 (0.80, 2.20) | 1.50 (0.77, 2.93) | |
| Diagnosed on admission | 41/1317 (3.1) | 0.79 (0.38, 1.63) | – | |
| Ethnicity | 1035 | |||
| EU | 641/1035 (61.9) | 1 | 1 | |
| MENA | 196/1035 (18.9) | 0.98 (0.69, 1.40) | 0.87 (0.52, 1.47) | |
| AC | 174/1035 (16.8) | 0.96 (0.66, 1.40) | 0.78 (0.44, 1.37) | |
| AS | 24/1035 (2.3) | 1.51 (0.65, 3.52) | – | |
| BMI (kg/m2) | 1117 | 28.4 [25.0–32.7] | 1.25 (1.09, 1.42) | 0.95 (0.78, 1.16) |
| BMI class | 1117 | |||
| < 25 kg/m2 | 279/1117 (25) | 1 | 1 | |
| 25–29.9 kg/m2 | 410/1117 (36.7) | 1.33 (0.93, 1.89) | 0.70 (0.42, 1.16) | |
| 30–39.9 kg/m2 | 359/1117 (32.1) | 1.71 (1.20, 2.43) | 0.76 (0.45, 1.27) | |
| ≥ 40 kg/m2 | 69/1117 (6.2) | 1.28 (0.70, 2.32) | 0.74 (0.29, 1.84) | |
| Diabetes duration (years) | 772 | 13.6 ± 10.9 | 1.00 (0.98, 1.01) | 1.01 (0.99, 1.04) |
| HbA1c (mmol/mol) | 846 | 65.4 ± 21.2 | 0.99 (0.99, 1.00) | 1.00 (0.99, 1.02) |
| HbA1c (%) | 846 | 8.1 ± 1.9 | 0.94 (0.86, 1.03) | 1.02 (0.87, 1.19) |
| HbA1c (categories) | 846 | |||
| < 53 mmol/mol (7%) | 245/846 (29.0) | 1 | 1 | |
| 53–63 mmol/mol (7–7.9%) | 228/846 (27.0) | 0.84 (0.55, 1.27) | 1.55 (0.82, 2.93) | |
| 64–74 mmol/mol (8–8.9%) | 164/846 (19.4) | 0.92 (0.59, 1.45) | 1.09 (0.52, 2.28) | |
| ≥ 75 mmol/mol (9%) | 209/846 (24.7) | 0.78 (0.51, 1.21) | 0.84 (0.40, 1.75) | |
| Hypertension | 1299 | 1003/1299 (77.2) | 1.23 (0.92, 1.65) | 1.82 (1.11, 2.98) |
| Dyslipidaemia | 1255 | 640/1255 (51.0) | 1.07 (0.84, 1.37) | 1.21 (0.84, 1.74) |
| Tobacco use | 1029 | |||
| Never | 582/1029 (56.6) | 1 | 1 | |
| Former | 390/1029 (37.9) | 1.21 (0.91, 1.61) | 1.00 (0.64, 1.57) | |
| Current | 57/1029 (5.5) | 1.54 (0.87, 2.74) | 1.20 (0.49, 2.93) | |
| Long, term diabetes complications | ||||
| Microvascular complications | 883 | 413/883 (46.8) | 1.28 (0.94, 1.73) | 5.25 (3.03, 9.10) |
| Severe diabetic retinopathy | 954 | 66/954 (6.9) | 1.22 (0.71, 2.11) | 2.05 (1.03, 4.07) |
| Diabetic kidney disease | 1066 | 355/1066 (33.3) | 1.03 (0.78, 1.37) | 3.19 (2.09, 4.87) |
| History of diabetic foot ulcer | 1232 | 76/1232 (6.2) | 0.67 (0.38, 1.18) | 1.53 (0.79, 2.99) |
| Macrovascular complications | 1189 | 485/1189 (40.8) | 1.18 (0.91, 1.52) | 3.58 (2.41, 5.31) |
| Ischaemic heart disease (ACS/CAR) | 1251 | 336/1251 (26.9) | 1.04 (0.79, 1.37) | 2.65 (1.84, 3.82) |
| Cerebrovascular disease (stroke or TIA) | 1267 | 163/1267 (12.9) | 1.02 (0.71, 1.47) | 2.19 (1.40, 3.42) |
| Peripheral artery disease (major amputation/LLAR) | 1285 | 145/1285 (11.3) | 0.91 (0.61, 1.34) | 1.97 (1.23, 3.17) |
| Comorbidities | ||||
| Heart failure | 1206 | 140/1206 (11.6) | 0.78 (0.52, 1.17) | 2.28 (1.42, 3.66) |
| NAFLD or liver cirrhosis | 1107 | 119/1107 (10.7) | 1.23 (0.81, 1.86) | 0.70 (0.34, 1.41) |
| Active cancer | 1282 | 194/1282 (15.1) | 1.08 (0.77, 1.50) | 1.55 (0.99, 2.42) |
| COPD | 1278 | 133/1278 (10.4) | 0.96 (0.64, 1.43) | 1.36 (0.80, 2.32) |
| Treated OSA | 1189 | 144/1189 (12.1) | 1.44 (0.99, 2.08) | 1.81 (1.12, 2.93) |
| Organ graft | 1302 | 38/1302 (2.9) | 1.14 (0.57, 2.28) | 0.46 (0.11, 1.93) |
| End stage renal failure | 831 | 60/831 (7.2) | 0.66 (0.35, 1.27) | 0.62 (0.24, 1.60) |
| Routine treatment before admission | ||||
| Metformin | 1317 | 746/1317 (56.6) | 0.95 (0.75, 1.21) | 0.59 (0.42, 0.84) |
| Sulfonylurea/glinides | 1317 | 367/1317 (27.9) | 1.03 (0.79, 1.34) | 0.74 (0.49, 1.13) |
| DPP-4 inhibitors | 1317 | 285/1317 (21.6) | 1.01 (0.75, 1.34) | 0.85 (0.55, 1.32) |
| GLP1-RA | 1317 | 123/1317 (9.3) | 1.36 (0.92, 2.01) | 0.64 (0.32, 1.29) |
| Insulin | 1317 | 504/1317 (38.3) | 1.01 (0.79, 1.29) | 1.71 (1.20, 2.43) |
| Loop diuretics | 1317 | 252/1317 (19.1) | 1.10 (0.81, 1.48) | 2.49 (1.70, 3.64) |
| Thiazide diuretics | 1317 | 267/1317 (20.3) | 1.08 (0.81, 1.45) | 0.98 (0.63, 1.52) |
| Potassium-sparing diuretics | 1317 | 59/1317 (4.5) | 1.17 (0.67, 2.05) | 1.77 (0.88, 3.58) |
| MRA | 1317 | 53/1317 (4.0) | 0.96 (0.52, 1.78) | 2.03 (1.00, 4.13) |
| β-blockers | 1317 | 442/1317 (33.6) | 1.03 (0.80, 1.32) | 1.84 (1.29, 2.62) |
| ACE inhibitors | 1317 | 354/1317 (26.9) | 1.17 (0.90, 1.52) | 1.43 (0.99, 2.08) |
| ARBs | 1317 | 389/1317 (29.5) | 1.22 (0.94, 1.57) | 1.15 (0.79, 1.67) |
| ARBs and/or ACE inhibitors | 1317 | 737/1317 (56.0) | 1.32 (1.03, 1.68) | 1.58 (1.09, 2.28) |
| ARBs and/or ACE inhibitors and/or MRA | 1317 | 752/1317 (57.1) | 1.29 (1.01, 1.65) | 1.67 (1.15, 2.43) |
| Statins | 1317 | 627/1317 (47.6) | 1.03 (0.81, 1.31) | 1.19 (0.84, 1.68) |
Data are presented as numbers (%) and mean ± SD, or median [25th–75th percentile] if not normally distributed
OR corresponds to an increase of 1 unit of any quantitative variable, except for BMI. BMI was natural log transformed before OR calculation, which corresponds to an increase of 1 SD
Ethnicity: EU (Europid), MENA (Middle East North Africa); AC (African or Caribbean), AS (Asian)
HbA1c corresponds to the HbA1c value determined in the 6 months prior to or in the first 7 days following hospital admission
Diabetic kidney disease defined as eGFR ≤60 ml min−1 [1.73 m]−2 and/or proteinuria
MRAs include spironolactone and eplerenone
ACS, acute coronary syndrome; CAR, coronary artery revascularisation; COPD, chronic obstructive pulmonary disease; GLP1-RA, glucagon-like peptide 1-receptor agonist; LLAR, lower limb artery revascularisation; NAFLD, non-alcoholic fatty liver disease; TIA, transient ischaemic attack